Dystrophin – Talk Bio

Wave Life Sciences’ WVE-N531 Shows Promise in Duchenne Muscular Dystrophy Treatment

4 weeks ago talkbio0Tagged Approved, Dystrophin, Gene Expression, Health Improvement, Muscle Tissue, Muscular Dystrophy, Duchenne, Phase 2 Clinical Trials, skipping, United States Food and Drug Administration, WVE-N531

Duchenne muscular dystrophy (DMD), WVE-N531, exon 53 skipping, Phase II trial, dystrophin expression, muscle health improvement, FDA approval

Avidity’s Del-zota Shows Promise in Duchenne Muscular Dystrophy Treatment

1 month ago talkbio0Tagged Creatine Kinase, Del-zota, DMD, Dystrophin, exon, Muscular Dystrophy, Duchenne, production, RNA, safety profile, skipping

Del-zota, Duchenne muscular dystrophy (DMD), RNA therapeutics, exon 44 skipping, dystrophin production, creatine kinase reduction, safety profile

Wave Life Sciences Reports Positive Interim Data for Duchenne Muscular Dystrophy Treatment

7 months ago talkbio0Tagged Clinical Trials, DMD, Does skip, Duchenne, Dystrophin, exon 53, FORWARD-53, Gene Expression, Interim, Muscular Dystrophy, Muscular Dystrophy, Duchenne, Wave Life Sciences, WVE-N531

Wave Life Sciences, Duchenne Muscular Dystrophy, DMD, Exon 53 Skipping, WVE-N531, FORWARD-53 Clinical Trial, Interim Data, Muscle Health, Dystrophin Expression